Zobrazeno 1 - 10
of 143
pro vyhledávání: '"Michael R Ehrenstein"'
Autor:
Peter C. Taylor, Ayman Askari, Ernest Choy, Michael R. Ehrenstein, Sara Else, Muhammad K. Nisar
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint pain and stiffness. Biologics represent some of the most effective treatments for RA, but previous guidance from the National Institute for
Externí odkaz:
https://doaj.org/article/7b0471b44dda43c790c34ef8738fd283
Publikováno v:
Revista Portuguesa de Nefrologia e Hipertensão, Vol 36, Iss 3, Pp 127-129 (2022)
Externí odkaz:
https://doaj.org/article/26cd880b2e0e4e96a357d82075ee6303
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-8 (2020)
Abstract Background There is limited evidence that rituximab, a B cell depletion therapy, is an effective treatment for systemic lupus erythematosus (SLE). Data on the mechanisms of B cell depletion in SLE indicate that the combination of rituximab a
Externí odkaz:
https://doaj.org/article/9d436fbce3974f05b19383d9cdf4bd7f
Autor:
Dao X. Nguyen, Helen M. Baldwin, Amara N. Ezeonyeji, Mohammed Rohan Butt, Michael R. Ehrenstein
Publikováno v:
iScience, Vol 24, Iss 9, Pp 102973- (2021)
Summary: Regulatory T cells (Treg) prevent the migration of effector T cells toward sites of inflammation, thereby limiting disease progression. We investigated this aspect of Treg function using psoriatic arthritis (PsA) as an exemplar of chronic in
Externí odkaz:
https://doaj.org/article/c68d354117f2470399042318fcd4a655
Autor:
Gabriella Szylar, Riccardo Wysoczanski, Helina Marshall, Daniel J. B. Marks, Ricardo José, Michael R. Ehrenstein, Jeremy S. Brown
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/f69b031dd553498881be5b31e25d18cb
Autor:
Muhammad Shipa, Liliana R Santos, Dao X Nguyen, Andrew Embleton-Thirsk, Mariea Parvaz, Lauren L Heptinstall, Ruth J Pepper, David A Isenberg, Caroline Gordon, Michael R Ehrenstein
Publikováno v:
The Lancet Rheumatology. 5:e24-e35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::187102e60d9bcfcbf501ff4eb67c437b
https://doi.org/10.1016/s2665-9913(22)00332-0
https://doi.org/10.1016/s2665-9913(22)00332-0
Autor:
Michael R. Ehrenstein, Muhammad Shipa
Publikováno v:
Journal of Experimental Medicine. 220
In this Viewpoint we discuss how experimental medicine applied in the setting of clinical trials can address unmet need in the prototypic autoimmune disease systemic lupus erythematosus (SLE) to improve outcomes for patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5273a95e8acdcbd73a47c038f72a4729
https://doi.org/10.1084/jem.20230559
https://doi.org/10.1084/jem.20230559
Autor:
Muhammad R A Shipa, Mariea Parvaz, Dao X Nguyen, Liliana Ribeiro Santos, David A Isenberg, Caroline Gordon, Michael R Ehrenstein
Publikováno v:
Rheumatology. 62
Background/Aims The BEAT-lupus double-blind randomised trial demonstrated that belimumab (anti-BAFF antibody) reduced the number of severe-flares (compared to placebo) after B-cell depletion (rituximab) in patients with systemic lupus erythematosus (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9834509bd080a60f4115880a2c9e219f
https://doi.org/10.1093/rheumatology/kead104.025
https://doi.org/10.1093/rheumatology/kead104.025
Autor:
Muhammad R A Shipa, Lawrence Langley, Benjamin Sacks, Su-Ann Yeoh, M D Mainuddin, Dev Mukerjee, Madhura Castelino, Michael R Ehrenstein
Publikováno v:
Rheumatology (Oxford)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba7dcb8d2e4089803899d47eb8a51020
https://doi.org/10.1093/rheumatology/keac276
https://doi.org/10.1093/rheumatology/keac276
Autor:
Rose M. Gilbert, Xiaozhe Zhang, Robert D. Sampson, Michael R. Ehrenstein, Dao X. Nguyen, Mahid Chaudhry, Charles Mein, Nadiya Mahmud, Grazyna Galatowicz, Oren Tomkins-Netzer, Virginia L. Calder, Sue Lightman
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
BackgroundNon-infectious uveitis can cause chronic relapsing and remitting ocular inflammation, which may require high dose systemic immunosuppression to prevent severe sight loss. It has been classically described as an autoimmune disease, mediated
Externí odkaz:
https://doaj.org/article/b42b99a840f043ffb206c156e89239dc